The number of elderly patients diagnosed with colon cancer continues to increase worldwide, in parallel with population aging 1 . However, no guideline for the management of colon cancer in this population has been established because elderly patients generally have been excluded from randomized control studies 2 . A recent review has highlighted the problems of a lack of evidence and under-representation of elderly patients in clinical trials on the specific effects of adjuvant chemotherapy in elderly patients because of strict age-based inclusion and exclusion criteria 3 . In one study of data from Medicare and the Texas Cancer Registry, Zhao and colleagues reported that guideline-concordant treatment, including adjuvant chemotherapy, was associated with better survival outcomes among elderly patients with stage II and stage III colon cancer 4 . However, elderly patients tend to have a poorer general condition, compared to their younger counterparts, and may therefore face an increased risk of morbidity and mortality associated with chemotherapy-related adverse effects [5] [6] [7] . The effect of adjuvant chemotherapy after curative resection in stage II colon cancer patients remains controversial. Some studies reported that adjuvant chemotherapy confers survival benefits 8, 9 , whereas other recent studies suggest a lack of association with improved survival gain [9] [10] [11] [12] . However, as most previous studies did not focus on patients older than 70 years, little information is available about the potential benefits of adjuvant chemotherapy for stage II colon cancer in this population. Therefore, we aimed to investigate the oncologic outcomes, including recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS), in elderly patients with stage II colon cancer who underwent curative resection with or without adjuvant chemotherapy. We hypothesize that these two groups of patients would achieve different survival outcomes.
Statistical analysis. SPSS version 25.0 for Windows (IBM Corp, Armonk, NY, USA) was used for the statistical analysis. A p value < 0.05 was considered statistically significant. Categorical baseline characteristics were analyzed using the χ 2 -test or linear-by-linear association, and continuous variables were analyzed using Student's t-test. The two groups of patients were balanced using propensity score matching, which included a logistic regression with 1:1 nearest neighbor matching and a caliper of 0.2. The following covariables included: age, sex, 
Results
A total of 623 patients underwent curative resection at our institution between 2002 and 2015. Of these, 63 patients and 34 patients were excluded because of a history of other malignancy and missing data, respectively. Finally, 526 patients were included in our analysis (Fig. 1) . Their baseline characteristics are presented in Table 1 . Briefly, the overall mean age was 75.7 years (range: 70-93 years), and there was a slight male predominance (300/526, 57%).
In an initial group comparison, patients in the SA group were older and had a lower BMI, higher ASA classification, larger tumor size and more frequent venous invasion, compared to the AC group. After propensity score matching to balance the pre-existing and pathologic variables, 145 patients were assigned to each arm. The mean ages of the matched SA and AC groups were 74.3 and 74.0 years, respectively (Table 2 ). In the AC group, after propensity score matching, the regimens followed were: 5-FU (n = 61), capecitabine (n = 40), capecitabine and oxaliplatin (n = 1), uracil/tegafur (UFT; n = 18), folinic acid-FU-oxaliplatin (FOLFOX; n = 21), and unknown (as the patients received chemotherapy at other hospitals; n = 4).
Recurrence-free survival (RFS).
All patients were followed to detect recurrence for a mean of 1337.7 days (range: 15-3403 days). Recurrence was detected in 11 (7.6%) and 20 patients (13.8%) in the SA and AC groups, respectively, which had median RFS durations of 79.8 (95% confidence interval [CI]: 75.8-83.9) and 96.1 months (Fig. 3) . This difference was not statistically significant (log-rank test, p = 0.486).
The median OS durations in the SA and AC groups were 117.3 (95% CI: 107.2-127.4) and 124.5 months (95% CI: 113.4-135.5) months, respectively (Fig. 4) . The corresponding 5-year OS rates were 81.4 and 85.2%, and this difference was not statistically significant (log-rank test, p = 0.299).
factors associated with RfS, cSS and oS. RFS. In a univariable analysis, age, pulmonary disease, preoperative CEA level and lymphatic, venous and perineural invasion were identified as statistically significant factors for RFS. In a multivariable analysis, the CEA level (hazard ratio [HR]: 1.01, 95% CI: 1.00-1.01), venous invasion (HR: 3.57, 95% CI: 1.15-11.06) and perineural invasion (HR: 3.40, 95% CI: 1.47-7.85) remained independent and significant factors affecting RFS (Table 3) . However, adjuvant chemotherapy was not identified as a significant factor (HR: 1.61, 95% CI: 0.77-3.36).
CSS. In a univariable analysis, age, BMI, obstruction, preoperative CEA level, tumor size, pathologic T stage, venous and perineural invasion and postoperative complications were identified as statistically significant factors affecting CSS. In a multivariable analysis, CEA (HR: 1.01, 95% CI: 1.00-1.01), tumor size (HR: 1.19, 95% CI: 1.02-1.40) and venous (HR: 5.55, 95% CI: 2.04-15.06) and perineural invasion (HR: 2.34, 95% CI: 1.03-5.29) remained independent and significant factors affecting CSS (Table 3) . Again, however, adjuvant chemotherapy was not statistically significant (HR: 0.79, 95% CI: 0.41-1.53).
OS. In a univariable analysis, age, sex, BMI, ASA, pulmonary disease, perforation, obstruction, preoperative CEA level, tumor size, pathologic T stage, postoperative complications and lymphatic, venous and perineural invasion were identified as statistically significant. In a multivariable analysis, female sex (HR: 0.40, 95% CI: 0.21-0.73), pulmonary disease (HR: 3.02, 95% CI: 1.20-7.59), CEA (HR: 1.01, 95% CI 1.00-1.01), obstruction (HR: 1.79, 95% CI: 1.03-3.10), size (HR: 1.21, 95% CI: 1.07-1.37), harvested LN ( > 12) (HR: 0.37, 95% CI: 0.19-0.70), and venous invasion (HR: 3.41, 95% CI: 1.38-8.42) were independent factors affecting OS (Table 3) . However, adjuvant chemotherapy was not a statistically significant factor (HR: 0.77, 95% CI: 0.48-1.26).
Subgroup analysis.
We further divided patients into low-and high-risk subgroups to analyze the effect of adjuvant chemotherapy. The high-risk subgroup was defined as patients who fulfilled one or more of the following criteria: poorly differentiated histology, perforation, bowel obstruction, < 12 examined LNs, lymphatic/ vascular invasion, and perineural invasion. However, this factor did not affect RFS, CSS, or OS in either the low-or high-risk patient subgroups. A multivariable analysis revealed no significant factors (Table 4) . Finally, we analyzed the factors affecting RFS, CSS and OS in the AC group. Notably, perineural invasion was an independent factor affecting RFS (HR: 5.03, 95% 1.89-13.40) and CSS (HR: 3.99, 95% CI 1.24-12.84), while obstruction (Table 5) .
To evaluate the effect of adding oxaliplatin to 5-FU in elderly patients, we divided the patients who received chemotherapy into two groups: those who received 5-FU (n = 119) and those who received 5-FU and oxaliplatin (n = 22). There was no statistically significant difference in the 5-year RFS (86.5% vs. 70.2%, log-rank p = 0.111), CSS (90.2% vs. 87.9%, log-rank p = 0.743), or OS (86.3% vs. 87.9%, log-rank p = 0.816) between the two groups. Moreover, adding oxaliplatin did not significantly affect the RFS (HR 2.24, 95% CI 0.81-6.62), CSS (HR 0.84, 95% CI 0.20-3.60), or OS (HR 0.84, 95% CI 0.20-3.60).
Discussion
Our study shows that postoperative adjuvant chemotherapy confers no major survival benefit in patients older than 70 years with stage II colon cancer, even after propensity score matching. Additionally, adjuvant chemotherapy did not affect the RFS, CSS, or OS outcomes even in patients with high-risk features. These findings may have a positive impact on many patients, especially those at an advanced age, who can avoid the problems associated with chemotherapy.
As noted previously, no consensus has been reached regarding the effect of adjuvant chemotherapy for stage II colon cancer. The QUASAR trial reported improved survival outcomes in patients with stage II colon cancer who received chemotherapy comprising FU and folinic acid 9 , while Casadaban et al. reported better OS in patients with stage II colon cancer included in a national cancer database 8 . However, recent studies including elderly patients, in contrast to the QUASAR trial and the study by Casadaban et al., have failed to demonstrate an effect of adjuvant chemotherapy. For example, Booth et al. reported no benefit of adjuvant chemotherapy in terms of CSS and OS even in high-risk patients in a population-based study 14 , consistent with our findings. These results suggest that management guidelines for stage II patients should be redefined.
There is some debate about the role of chemotherapy in elderly patients with colorectal cancer. The Adjuvant Colon Cancer End Points Collaborative Group showed that elderly patients (aged ≥70 years) with stage II/ III colon cancer did not experience a statistically significant benefit from adjuvant chemotherapy in terms of disease-free survival (HR, 1.05; 95% CI, 0.94 to 1.19) and OS (HR, 1.08; 95% CI, 0.95 to 1.23) 15 . Popescu et al., in their study of first-line chemotherapy for patients with advanced colorectal cancer in elderly patients (≥70), reported that the median OS period was shorter in the elderly group than in younger patients (292 vs. 350 days, p = 0.04) 16 . Strowitzki et al. showed that even in a total of 468 patients with colorectal liver metastases the administration of neoadjuvant chemotherapy is of questionable value 17 . 
